Onconova Therapeutics to Attend the Sachs 21st Annual Biotech in Europe Forum (BEF)
September 29, 2021 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for...
Onconova Therapeutics Announces Encouraging Clinical Data Supporting the Anti-Cancer Activity of Rigosertib-Nivolumab Combination in Advanced KRAS+ Non-Small Cell Lung Cancer
September 22, 2021 08:00 ET
|
Onconova Therapeutics, Inc.
Preliminary Phase 1/2a trial data show an early signal of activity in extensively pre-treated population with 2 partial responses out of 7 evaluable patients Responses were seen in patients with...
Onconova Therapeutics Announces Upcoming Presentation at the 3rd Annual RAS Targeted Drug Development Summit
September 20, 2021 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for...
Onconova Therapeutics Announces Participation at the Upcoming H.C. Wainwright 23rd Annual Global Investment Conference
September 09, 2021 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for...
Coherus BioSciences Announces Upcoming Medical Conference Presentations
September 08, 2021 08:30 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced upcoming medical conference presentations. Toripalimab clinical data...
Onconova Therapeutics Provides an Update on the Phase 1/2a Trial of Rigosertib-Nivolumab Combination in KRAS+ Non-Small Cell Lung Cancer
June 28, 2021 08:00 ET
|
Onconova Therapeutics, Inc.
Expansion of trial underway at highest dose in the current protocol, and continued dose escalation under consideration Preliminary data support the preclinical observation of rigosertib augmenting...
GENECAST begins clinical research on early diagnosis of lung cancer with Samsung Medical Center
June 14, 2021 05:59 ET
|
GENECAST
Will it be possible to administer EGFR inhibitors to patients with early-stage non-small cell lung cancer (NSCLC)?The real possibility of the commercial use of liquid biopsies for patients with stage...
Vaccinex Announces Publication of Results from CLASSICAL-Lung Phase 1b/2 Clinical Trial in Non-Small Cell Lung Cancer in the Peer-Reviewed Journal Clinical Cancer Research
April 21, 2021 08:00 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., April 21, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and...
Correction: Non-Small Cell Lung Cancer Pipeline Expected to Offer Myriad of Novel Therapies in the Next Decade
November 06, 2020 02:34 ET
|
DelveInsight Business Research LLP
Los Angeles, USA, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Non-Small Cell Lung Cancer Pipeline Expected to Offer Myriad of Novel Therapies in the Next Decade The Non-Small Cell Lung Cancer Pipeline...
Non-Small Cell Lung Cancer Pipeline Expected to Offer Myriad of Novel Therapies in the Next Decade
November 02, 2020 10:17 ET
|
DelveInsight Business Research LLP
Los Angeles, USA, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Non-Small Cell Lung Cancer Pipeline Expected to Offer Myriad of Novel Therapies in the Next Decade The Non-Small Cell Lung Cancer Pipeline...